Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan as Neoadjuvant Therapy in Non-Urothelial Muscle Invasive Bladder Cancer
NCT05581589Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in muscle-invasive bladder cancer (MIBC), sponsored by University of Washington. Started Jun 2023; status: terminated.
02
Drugs
sacituzumab govitecan
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05581589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581589.